Hamid Sayar MD
Hematologic Oncology
Faculty, Indiana University School of Medicine
1030 W. Michigan St.2nd FloorIndianapolis, IN 46202
Overview of Dr. Sayar
Dr. Hamid Sayar is an oncologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Indiana University Health University Hospital, Indiana University Health Tipton Hospital, and Eskenazi Health. He received his medical degree from Tehran University of Medical Sciences School of Medicine and has been in practice 34 years. Dr. Sayar accepts several types of health insurance, listed below. He is one of 41 doctors at Eskenazi Health and one of 119 doctors at Indiana University Health University Hospital who specialize in Oncology. He has more than 20 publications and over 500 citings.
Education & Training
University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2003 - 2004
Tehran University of Medical Sciences School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 2011 - 2028
IN State Medical License 2007 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification HealtheLife and PowerChart, Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2015-2017
Clinical Trials
- Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Apr 01
- Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype Start of enrollment: 2012 Feb 10
Publications & Presentations
PubMed
- FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.Santhosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, Kanaka Sai Ram Padam, Larry D Cripe
NPJ Precision Oncology. 2026-02-26 - 1 citationsSpinal Cord Compression As the Initial Manifestation of Relapsed Acute Myeloid Leukemia: A Case Report and Literature Review of a Rare Presentation.Raul Gregg-Garcia, Hamid Sayar
Cureus. 2025-03-01 - 15 citationsNCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand
Journal of the National Comprehensive Cancer Network. 2025-03-01
Insurance Accepted
- Aetna Choice POS II
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOGreat West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
